Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20924695 | 0.84 | MAOB (0.43) | MIFMAOBMEN1KMT2AALOX15 | |
| SCHEMBL12998131 | 0.80 | MIF (0.42) | MIFMAOBMEN1KMT2AALOX15 | |
| SCHEMBL2601487 | 0.80 | MIF (0.42) | MIFMAOBMEN1KMT2AALOX15 | |
| SCHEMBL22261555 | 0.80 | MIF (0.42) | MIFMAOBMEN1KMT2AALOX15 | |
| SCHEMBL18796296 | 0.80 | MAOB (0.49) | MIFMAOBMEN1KMT2AALOX15 | |
| SCHEMBL10446873 | 0.80 | MIF (0.42) | MIFMAOBMEN1KMT2AALOX15 | |
| SCHEMBL10446552 | 0.78 | MIF (0.43) | MIFMAOBMEN1KMT2AALOX15 | |
| SCHEMBL15143562 | 0.78 | ACHE (0.43) | MIFMAOBALDH1A1AKR1B1TP53 | |
| SCHEMBL2601430 | 0.78 | PIM1 (0.44) | MIFMAOBMEN1KMT2AALOX15 | |
| SCHEMBL2601428 | 0.76 | ALDH1A1 (0.49) | MIFMAOBMEN1KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10596171-B2 | Cap-dependent endonuclease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2020-03-24 | — | — | US | disclosed |
| WO-2019144089-A1 | CAP-DEPENDENT ENDONUCLEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-07-25 | — | — | WO | disclosed |
| US-20190224198-A1 | CAP-DEPENDENT ENDONUCLEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224198-A1 | CAP-DEPENDENT ENDONUCLEASE INHIBITORS | RNGTT, RNASEH1, RNASEL | MIF 2881/4885MAOB 317/4885MEN1 3256/4885 |
| US-10596171-B2 | Cap-dependent endonuclease inhibitors | RNGTT, RNASEH1, RNASEL | MIF 2881/4885MAOB 317/4885MEN1 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.